03/14/23 7:05 AMNasdaq : VIRI earningslow floatVirios Therapeutics Announces Fourth Quarter and Full Year 2022 Financial ResultsVirios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”), today announced financial resultsRHEA-AIneutral
03/07/23 7:05 AMNasdaq : VIRI conferencesearningslow floatVirios Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 14, 2023Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”), announced today that it will report fourth quarterRHEA-AIneutral
02/13/23 7:05 AMNasdaq : VIRI covid-19low floatVirios Therapeutics Announces Exploratory Long-COVID Trial Top-Line Data, Featuring Combination of Valacyclovir and Celecoxib, Projected in June 2023Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases including fibromyalgia (“FM”), announced today that it expects top-lineRHEA-AIneutral
01/05/23 7:00 AMNasdaq : VIRI clinical triallow floatVirios Therapeutics Announces Scheduling of FDA Meeting in March 2023 to Discuss IMC-1 Fibromyalgia Phase 3 ProgramVirios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases including fibromyalgia (“FM”), announced today that its end-of-Phase 2RHEA-AIneutral
11/29/22 7:05 AMNasdaq : VIRI conferenceslow floatVirios Therapeutics, Inc. to Present at the Virtual Planet MicroCap ShowcaseVirios Therapeutics, Inc., a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, today announced that Greg Duncan, Chairman and CEO of Virios Therapeutics will be attending and presenting at the Planet MicroCap Showcase, which is taking...RHEA-AIneutral
11/14/22 7:05 AMNasdaq : VIRI earningslow floatVirios Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate UpdateVirios Therapeutics, Inc., a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases including fibromyalgia, today announced financial results for the third quarter ended September 30, 2022, as well as plans to advance development of its lead antiviral development...RHEA-AIneutral
11/03/22 7:05 AMNasdaq : VIRI conferencesearningslow floatVirios Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Monday, November 14, 2022Virios Therapeutics, Inc., a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today that its third quarter 2022 financial results will be reported on Monday, November 14, 2022 before the open of the financial markets.RHEA-AIneutral
09/22/22 4:15 PMNasdaq : VIRI offeringlow floatVirios Therapeutics, Inc. Announces Closing of Public OfferingVirios Therapeutics, Inc., a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today the closing of its previously announced underwritten public offering of 10.0 million shares of its common stock at a public offering price of...RHEA-AIneutral
09/19/22 10:04 PMNasdaq : VIRI offeringlow floatVirios Therapeutics, Inc. Announces Pricing of Public OfferingVirios Therapeutics, Inc., a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today the pricing of its underwritten public offering of 10.0 million shares of its common stock at a public offering price of $0.50 per share, for...RHEA-AIneutral
09/19/22 4:05 PMNasdaq : VIRI offeringlow floatVirios Therapeutics, Inc. Announces Proposed Public OfferingVirios Therapeutics, Inc., a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today that it intends to offer to sell shares of its common stock in an underwritten public offering. ThinkEquity is acting as sole book-running...RHEA-AIneutral